123 related articles for article (PubMed ID: 38061174)
21. Ototoxicity in children treated for osteosarcoma.
Lewis MJ; DuBois SG; Fligor B; Li X; Goorin A; Grier HE
Pediatr Blood Cancer; 2009 Mar; 52(3):387-91. PubMed ID: 19061216
[TBL] [Abstract][Full Text] [Related]
22. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
23. Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin.
Sriyapai T; Thongyai K; Phuakpet K; Vathana N; Buaboonnam J; Sanpakit K
Turk J Pediatr; 2022; 64(3):531-541. PubMed ID: 35899566
[TBL] [Abstract][Full Text] [Related]
24. Is Methotrexate Ototoxic? Investigating the Ototoxic Late Effects of Pediatric Cancer Treatment.
Moore B; Sheets G; Doss J; Umrigar A; Norman M; Fang Z; Prasad P; Musso A; Clay S; Tsien F
Am J Audiol; 2023 Sep; 32(3):657-664. PubMed ID: 37532243
[TBL] [Abstract][Full Text] [Related]
25. Audiological profile of patients treated for childhood cancer.
Liberman PH; Goffi-Gomez MV; Schultz C; Novaes PE; Lopes LF
Braz J Otorhinolaryngol; 2016; 82(6):623-629. PubMed ID: 27156673
[TBL] [Abstract][Full Text] [Related]
26. Severity of hearing loss after platinum chemotherapy in childhood cancer survivors.
Strebel S; Mader L; Sláma T; Waespe N; Weiss A; Parfitt R; Am Zehnhoff-Dinnesen A; Kompis M; von der Weid NX; Ansari M; Kuehni CE
Pediatr Blood Cancer; 2022 Sep; 69(9):e29755. PubMed ID: 35723448
[TBL] [Abstract][Full Text] [Related]
27. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy.
Abujamra AL; Escosteguy JR; Dall'Igna C; Manica D; Cigana LF; Coradini P; Brunetto A; Gregianin LJ
Pediatr Blood Cancer; 2013 Mar; 60(3):474-8. PubMed ID: 22744939
[TBL] [Abstract][Full Text] [Related]
28. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.
Lafay-Cousin L; Purdy E; Huang A; Cushing SL; Papaioannou V; Nettel-Aguirre A; Bouffet E
Pediatr Blood Cancer; 2013 Feb; 60(2):287-92. PubMed ID: 23002030
[TBL] [Abstract][Full Text] [Related]
29. Ototoxicity from cisplatin therapy in childhood cancer.
Coradini PP; Cigana L; Selistre SG; Rosito LS; Brunetto AL
J Pediatr Hematol Oncol; 2007 Jun; 29(6):355-60. PubMed ID: 17551394
[TBL] [Abstract][Full Text] [Related]
30. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
Caballero M; Mackers P; Reig O; Buxo E; Navarrete P; Blanch JL; Grau JJ
Oncology; 2017; 93(2):75-82. PubMed ID: 28511189
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin ototoxicity in children: risk factors and its relationship with polymorphisms of DNA repair genes ERCC1, ERCC2, and XRCC1.
Turan C; Kantar M; Aktan Ç; Kosova B; Orman M; Bilgen C; Kirazlı T
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1333-1338. PubMed ID: 31586226
[TBL] [Abstract][Full Text] [Related]
32. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
33. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Das N; Kaushal D; Patro SK; Pareek P; Dixit A; Soni K; Prakasan Nair N; Choudhury B; Goyal A
Acta Otolaryngol; 2021 Sep; 141(9):885-893. PubMed ID: 34486907
[TBL] [Abstract][Full Text] [Related]
34. Cochrane corner: platinum-induced hearing loss after treatment for childhood cancer.
Brennan-Jones CG; McMahen C; Van Dalen EC
Int J Audiol; 2019 Apr; 58(4):181-184. PubMed ID: 30545270
[TBL] [Abstract][Full Text] [Related]
35. Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy.
Theunissen EA; Zuur CL; Józwiak K; Lopez-Yurda M; Hauptmann M; Rasch CR; van der Baan S; de Boer JP; Dreschler WA; Balm AJ
JAMA Otolaryngol Head Neck Surg; 2015 Sep; 141(9):810-5. PubMed ID: 26291150
[TBL] [Abstract][Full Text] [Related]
36. Hearing Loss Risk in Pediatric Patients Treated with Cranial Irradiation and Cisplatin-Based Chemotherapy.
Cohen-Cutler S; Wong K; Mena V; Sianto K; Wright MA; Olch A; Orgel E
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1488-1495. PubMed ID: 33677052
[TBL] [Abstract][Full Text] [Related]
37. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
38. Validation of Hearing Loss Prediction Tool for Cisplatin Chemotherapy and Radiation in Head and Neck Cancer Treatment.
Deutsch BC; Collopy C; Kallogjeri D; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2021 Feb; 147(2):182-189. PubMed ID: 33300954
[TBL] [Abstract][Full Text] [Related]
39. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
[TBL] [Abstract][Full Text] [Related]
40. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
Clemens E; de Vries AC; Pluijm SF; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; van Grotel M; van den Heuvel-Eibrink MM;
Eur J Cancer; 2016 Dec; 69():77-85. PubMed ID: 27821322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]